Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod
Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug approval last month, is targeting up to $150 million in a new funding round, according to a new ...
Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug approval last month, is targeting up to $150 million in a new funding round, according to a new ...
